Abbott loses pharma head
This article was originally published in The Gray Sheet
Executive Summary
Jeffrey Leiden, PhD, steps down as president of the firm's pharmaceutical products group, to be replaced by medical products group head Richard Gonzalez, effective March 27. The move makes Gonzalez president and COO for all operations of the corporation, Abbott says. The change comes as the company begins to focus more on the medical device side of its business with its impending $7 bil. acquisition of Guidant's vascular and endovascular businesses - the spoils of Boston Scientific's acquisition of Guidant (1"The Gray Sheet" March 20, 2006, p. 18)...